Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2010

01.12.2010 | Brief Report

Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report

verfasst von: Brunella Pilato, Simona De Summa, Katia Danza, Rossana Lambo, Angelo Paradiso, Stefania Tommasi

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Hereditary breast cancer syndrome was firstly associated with BRCA1 and BRCA2 genes the mutations of which confer high risk to develop breast and/or ovarian cancer. Double heterozygosity is a rare condition in which both BRCA1 and BRCA2 mutations are present in a family at the same time. In the current study, a family with double heterozygosity has been reported. Furthermore, for the first time a molecular analysis in both proband lineages, maternal and paternal, has been reported to understand the provenience of both germinal mutations.The case regards a woman who developed breast and ovarian cancer with liver metastasis which presented two mutations, each in the two genes, transmitted from her mother and her father, respectively. In this family all available members have been investigated. The concomitant presence of these peculiar mutations was never reported before suggesting a link with Caucasian population from Southern Italy.
Literatur
1.
Zurück zum Zitat Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, Digennaro M, Schittulli F, Lacalamita R, Paradiso A (2008) Molecular and in silico analysis of brca1 and brca2 variants. Mutat Res 644(1–2):64–70. doi:S0027-5107(08)00135-8 PubMed Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, Digennaro M, Schittulli F, Lacalamita R, Paradiso A (2008) Molecular and in silico analysis of brca1 and brca2 variants. Mutat Res 644(1–2):64–70. doi:S0027-5107(08)00135-8 PubMed
2.
Zurück zum Zitat Diez O, Gutierrez-Enriquez S, Masas M, Tenes A, Yague C, Arcusa A, Llort G (2010) Identification of a new complex deleterious mutation in exon 18 of the brca2 gene in a hereditary male/female breast cancer family. Breast Cancer Res Treat. doi:10.1007/s10549-010-0830-2 Diez O, Gutierrez-Enriquez S, Masas M, Tenes A, Yague C, Arcusa A, Llort G (2010) Identification of a new complex deleterious mutation in exon 18 of the brca2 gene in a hereditary male/female breast cancer family. Breast Cancer Res Treat. doi:10.​1007/​s10549-010-0830-2
3.
Zurück zum Zitat Pilato B, Martinucci M, Danza K, Pinto R, Petriella D, Lacalamita R, Bruno M, Lambo R, D’Amico C, Paradiso A, Tommasi S (2010) Mutations and polymorphic brca variants transmission in breast cancer familial members. Breast Cancer Res Treat. doi:10.1007/s10549-010-0861-8 Pilato B, Martinucci M, Danza K, Pinto R, Petriella D, Lacalamita R, Bruno M, Lambo R, D’Amico C, Paradiso A, Tommasi S (2010) Mutations and polymorphic brca variants transmission in breast cancer familial members. Breast Cancer Res Treat. doi:10.​1007/​s10549-010-0861-8
4.
Zurück zum Zitat Sluiter MD, van Rensburg EJ (2010) Large genomic rearrangements of the brca1 and brca2 genes: Review of the literature and report of a novel brca1 mutation. Breast Cancer Res Treat. doi:10.1007/s10549-010-0817-z Sluiter MD, van Rensburg EJ (2010) Large genomic rearrangements of the brca1 and brca2 genes: Review of the literature and report of a novel brca1 mutation. Breast Cancer Res Treat. doi:10.​1007/​s10549-010-0817-z
5.
Zurück zum Zitat Zuradelli M, Peissel B, Manoukian S, Zaffaroni D, Barile M, Pensotti V, Cavallari U, Masci G, Mariette F, Benski AC, Santoro A, Radice P (2010) Four new cases of double heterozygosity for brca1 and brca2 gene mutations: Clinical, pathological, and family characteristics. Breast Cancer Res Treat. doi:10.1007/s10549-010-0853-8 Zuradelli M, Peissel B, Manoukian S, Zaffaroni D, Barile M, Pensotti V, Cavallari U, Masci G, Mariette F, Benski AC, Santoro A, Radice P (2010) Four new cases of double heterozygosity for brca1 and brca2 gene mutations: Clinical, pathological, and family characteristics. Breast Cancer Res Treat. doi:10.​1007/​s10549-010-0853-8
6.
Zurück zum Zitat Cortesi L, Turchetti D, Bertoni C, Zanocco-Marani T, Vinceti M, Silvestri C, Federico M, Silingardi V, Ferrari S (2003) Italian family with two independent mutations: 3358t/a in brca1 and 8756dela in brca2 genes. Eur J Hum Genet 11(3):210–214. doi:10.1038/sj.ejhg.52009485200948 CrossRefPubMed Cortesi L, Turchetti D, Bertoni C, Zanocco-Marani T, Vinceti M, Silvestri C, Federico M, Silingardi V, Ferrari S (2003) Italian family with two independent mutations: 3358t/a in brca1 and 8756dela in brca2 genes. Eur J Hum Genet 11(3):210–214. doi:10.​1038/​sj.​ejhg.​52009485200948 CrossRefPubMed
7.
Zurück zum Zitat Musolino A, Naldi N, Michiara M, Bella MA, Zanelli P, Bortesi B, Capelletti M, Savi M, Neri TM, Ardizzoni A (2005) A breast cancer patient from Italy with germline mutations in both the brca1 and brca2 genes. Breast Cancer Res Treat 91(2):203–205. doi:10.1007/s10549-004-7704-4 CrossRefPubMed Musolino A, Naldi N, Michiara M, Bella MA, Zanelli P, Bortesi B, Capelletti M, Savi M, Neri TM, Ardizzoni A (2005) A breast cancer patient from Italy with germline mutations in both the brca1 and brca2 genes. Breast Cancer Res Treat 91(2):203–205. doi:10.​1007/​s10549-004-7704-4 CrossRefPubMed
8.
Zurück zum Zitat Tommasi S, Crapolicchio A, Lacalamita R, Bruno M, Monaco A, Petroni S, Schittulli F, Longo S, Digennaro M, Calistri D, Mangia A, Paradiso A (2005) Brca1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from apulia, Italy. Mutat Res 578(1–2):395–405. doi:S0027-5107(05)00250-2 PubMed Tommasi S, Crapolicchio A, Lacalamita R, Bruno M, Monaco A, Petroni S, Schittulli F, Longo S, Digennaro M, Calistri D, Mangia A, Paradiso A (2005) Brca1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from apulia, Italy. Mutat Res 578(1–2):395–405. doi:S0027-5107(05)00250-2 PubMed
9.
Zurück zum Zitat Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G (2002) Brcapro validation, sensitivity of genetic testing of brca1/brca2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701–2712CrossRefPubMed Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G (2002) Brcapro validation, sensitivity of genetic testing of brca1/brca2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701–2712CrossRefPubMed
10.
Zurück zum Zitat Leegte B, van der Hout AH, Deffenbaugh AM, Bakker MK, Mulder IM, ten Berge A, Leenders EP, Wesseling J, de Hullu J, Hoogerbrugge N, Ligtenberg MJ, Ardern-Jones A, Bancroft E, Salmon A, Barwell J, Eeles R, Oosterwijk JC (2005) Phenotypic expression of double heterozygosity for brca1 and brca2 germline mutations. J Med Genet 42(3):e20. doi:42/3/e20 CrossRefPubMed Leegte B, van der Hout AH, Deffenbaugh AM, Bakker MK, Mulder IM, ten Berge A, Leenders EP, Wesseling J, de Hullu J, Hoogerbrugge N, Ligtenberg MJ, Ardern-Jones A, Bancroft E, Salmon A, Barwell J, Eeles R, Oosterwijk JC (2005) Phenotypic expression of double heterozygosity for brca1 and brca2 germline mutations. J Med Genet 42(3):e20. doi:42/​3/​e20 CrossRefPubMed
11.
Zurück zum Zitat Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delag and 5382insc in brca1 and 6174delt in brca2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60(3):505–514PubMed Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delag and 5382insc in brca1 and 6174delt in brca2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60(3):505–514PubMed
12.
13.
Zurück zum Zitat Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K (2002) Ovarian cancer risk in Ashkenazi Jewish carriers of brca1 and brca2 mutations. Clin Cancer Res 8(12):3776–3781PubMed Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K (2002) Ovarian cancer risk in Ashkenazi Jewish carriers of brca1 and brca2 mutations. Clin Cancer Res 8(12):3776–3781PubMed
14.
Zurück zum Zitat Kataki A, Gomatos I, Pararas N, Armakolas A, Panousopoulos D, Karantzikos G, Voros D, Zografos G, Markopoulos C, Leandros E, Konstadoulakis M (2005) Identification of germline brca1 and brca2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals—correlation with clinicopathological data. Clin Genet 67(4):322–329. doi:CGE400 CrossRefPubMed Kataki A, Gomatos I, Pararas N, Armakolas A, Panousopoulos D, Karantzikos G, Voros D, Zografos G, Markopoulos C, Leandros E, Konstadoulakis M (2005) Identification of germline brca1 and brca2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals—correlation with clinicopathological data. Clin Genet 67(4):322–329. doi:CGE400 CrossRefPubMed
15.
Zurück zum Zitat De Benedetti VM, Radice P, Pasini B, Stagi L, Pensotti V, Mondini P, Manoukian S, Conti A, Spatti G, Rilke F, Pierotti MA (1998) Characterization of ten novel and 13 recurring brca1 and brca2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online. Hum Mutat 12(3):215 De Benedetti VM, Radice P, Pasini B, Stagi L, Pensotti V, Mondini P, Manoukian S, Conti A, Spatti G, Rilke F, Pierotti MA (1998) Characterization of ten novel and 13 recurring brca1 and brca2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online. Hum Mutat 12(3):215
16.
Zurück zum Zitat Armakolas A, Ladopoulou A, Konstantopoulou I, Pararas B, Gomatos IP, Kataki A, Konstadoulakis MM, Stathopoulos GP, Markopoulos C, Leandros E, Gogas I, Yannoukakos D, Androulakis G (2002) Brca2 gene mutations in Greek patients with familial breast cancer. Hum Mutat 19(1):81–82. doi:10.1002/humu.9003 CrossRefPubMed Armakolas A, Ladopoulou A, Konstantopoulou I, Pararas B, Gomatos IP, Kataki A, Konstadoulakis MM, Stathopoulos GP, Markopoulos C, Leandros E, Gogas I, Yannoukakos D, Androulakis G (2002) Brca2 gene mutations in Greek patients with familial breast cancer. Hum Mutat 19(1):81–82. doi:10.​1002/​humu.​9003 CrossRefPubMed
17.
Zurück zum Zitat Moslehi R, Russo D, Phelan C, Jack E, Antman K, Narod S (2000) An unaffected individual from a breast/ovarian cancer family with germline mutations in both brca1 and brca2. Clin Genet 57(1):70–73CrossRefPubMed Moslehi R, Russo D, Phelan C, Jack E, Antman K, Narod S (2000) An unaffected individual from a breast/ovarian cancer family with germline mutations in both brca1 and brca2. Clin Genet 57(1):70–73CrossRefPubMed
18.
Zurück zum Zitat Bell DW, Erban J, Sgroi DC, Haber DA (2002) Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both brca1 and brca2. Cancer Res 62(10):2741–2743PubMed Bell DW, Erban J, Sgroi DC, Haber DA (2002) Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both brca1 and brca2. Cancer Res 62(10):2741–2743PubMed
19.
Zurück zum Zitat Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of brca1 and brca2 among Ashkenazi Jews. N Engl J Med 336(20):1401–1408. doi:10.1056/NEJM199705153362001 CrossRefPubMed Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of brca1 and brca2 among Ashkenazi Jews. N Engl J Med 336(20):1401–1408. doi:10.​1056/​NEJM199705153362​001 CrossRefPubMed
20.
Zurück zum Zitat Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S (1999) Prevalence and penetrance of brca1 and brca2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91(14):1241–1247CrossRefPubMed Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S (1999) Prevalence and penetrance of brca1 and brca2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91(14):1241–1247CrossRefPubMed
21.
Zurück zum Zitat Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB (2001) The lifetime risks of breast cancer in Ashkenazi Jewish carriers of brca1 and brca2 mutations. Cancer Epidemiol Biomarkers Prev 10(5):467–473PubMed Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB (2001) The lifetime risks of breast cancer in Ashkenazi Jewish carriers of brca1 and brca2 mutations. Cancer Epidemiol Biomarkers Prev 10(5):467–473PubMed
22.
Zurück zum Zitat Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for brca1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94(18):1365–1372PubMed Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for brca1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94(18):1365–1372PubMed
24.
Zurück zum Zitat Claus EB, Petruzella S, Matloff E, Carter D (2005) Prevalence of brca1 and brca2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293(8):964–969. doi:293/8/964 CrossRefPubMed Claus EB, Petruzella S, Matloff E, Carter D (2005) Prevalence of brca1 and brca2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293(8):964–969. doi:293/​8/​964 CrossRefPubMed
Metadaten
Titel
Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report
verfasst von
Brunella Pilato
Simona De Summa
Katia Danza
Rossana Lambo
Angelo Paradiso
Stefania Tommasi
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1125-3

Weitere Artikel der Ausgabe 3/2010

Breast Cancer Research and Treatment 3/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.